Your browser is no longer supported. Please, upgrade your browser.
Settings
DBVT DBV Technologies S.A. daily Stock Chart
DBVT [NASD]
DBV Technologies S.A.
Index- P/E- EPS (ttm)-3.67 Insider Own- Shs Outstand24.70M Perf Week-3.73%
Market Cap509.65M Forward P/E- EPS next Y- Insider Trans- Shs Float21.54M Perf Month-16.78%
Income- PEG- EPS next Q- Inst Own50.54% Short Float5.10% Perf Quarter-8.76%
Sales11.81M P/S43.17 EPS this Y- Inst Trans- Short Ratio7.40 Perf Half Y-4.93%
Book/sh3.20 P/B6.45 EPS next Y- ROA- Target Price38.04 Perf Year-37.43%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range20.08 - 50.57 Perf YTD-16.14%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-59.72% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low1.47% ATR0.59
Employees244 Current Ratio- Sales Q/Q3.60% Oper. Margin- RSI (14)28.46 Volatility2.52% 2.42%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.07 Prev Close20.63
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume148.46K Price20.37
Recom1.70 SMA20-8.50% SMA50-11.24% SMA200-25.05% Volume62,770 Change-1.26%
Oct-31-17Upgrade Societe Generale Sell → Hold
Oct-24-17Downgrade Societe Generale Buy → Sell
Oct-23-17Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-23-17Initiated Deutsche Bank Buy $46
Mar-16-17Upgrade Societe Generale Hold → Buy
Sep-26-16Initiated JMP Securities Mkt Outperform
Dec-03-15Initiated Barclays Overweight $58
Oct-23-15Initiated BofA/Merrill Buy
Oct-13-15Initiated Jefferies Buy $47
Sep-15-15Initiated Morgan Stanley Overweight $59
Mar-18-15Initiated H.C. Wainwright Buy $50
Jun-15-18 08:46AM  Implied Volatility Surging for DBV Technologies (DBVT) Stock Options Zacks
Jun-11-18 11:01AM  DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Jun-05-18 01:31AM  DBV Technologies to Attend Upcoming Investor Conferences GlobeNewswire
Jun-04-18 08:30AM  Investor Expectations to Drive Momentum within Momo, Barrick Gold, Grupo Financiero Santander Mexico S.A. B. de C.V., DBV Technologies S.A., ICON, and SCIENCE APPLICATIONS INTERNATIONAL CORPORATION Discovering Underlying Factors of Influence GlobeNewswire
Jun-01-18 01:32AM  DBV Technologies: Ordinary and Extraordinary General Meeting of June 22, 2018 - Procedures for Obtaining Preparatory Documents for the General Meeting GlobeNewswire
May-29-18 01:04PM  DBV Technologies : Information regarding the total number of voting rights and total number of shares of the Company on May 18th, 2018 GlobeNewswire
01:31AM  DBV Technologies Shows Commitment to the Development of Treatments for Food Allergies at EAACI 2018 GlobeNewswire
May-16-18 01:32AM  DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors GlobeNewswire
May-14-18 12:31PM  DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
08:32AM  DBV Technologies Partners with FARE to Help Raise Awareness of Food Allergies in Support of the 21st Anniversary of Food Allergy Awareness Week GlobeNewswire
May-08-18 07:27AM  Want To Invest In DBV Technologies SA. (EPA:DBV)? Heres How It Performed Lately Simply Wall St.
01:32AM  DBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI Meeting GlobeNewswire
May-01-18 01:31AM  DBV Technologies to Attend Upcoming Investor Conferences GlobeNewswire
Apr-27-18 01:32AM  DBV Technologies Reports March 31, 2018 Cash Position GlobeNewswire
Apr-13-18 07:45AM  Investor Expectations to Drive Momentum within Criteo S.A, Prima BioMed, CoStar Group, DBV Technologies S.A, Hollysys Automation Technologies, and China Biologic Products Discovering Underlying Factors of Influence GlobeNewswire
Apr-05-18 12:01PM  DBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Apr-03-18 01:31AM  DBV Technologies to Attend the 11th Kempen Life Sciences Conference GlobeNewswire
Mar-26-18 09:57PM  DBV Technologies Announces Closing of Underwriters' Option to Purchase Additional Shares in Global Offering GlobeNewswire
Mar-23-18 04:02PM  DBV Technologies Announces Closing of Global Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares GlobeNewswire
Mar-21-18 03:02AM  DBV Technologies Announces Pricing of $150.0 million (122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares GlobeNewswire
Mar-20-18 04:02PM  DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares GlobeNewswire
Mar-16-18 04:32PM  DBV Technologies Announces Filing of 2017 "Document de Référence" and 2017 Annual Report on Form 20-F GlobeNewswire
Mar-14-18 10:46AM  DBV Technologies SA. (NASDAQ:DBVT): Should The Recent Earnings Drop Worry You? Simply Wall St.
08:25AM  Recent Analysis Shows SMART Global, DBV Technologies S.A, ICON, Adamas Pharmaceuticals, Shenandoah Telecommunications, and Costamare Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
02:32AM  DBV Technologies Reports Full Year 2017 Financial Results GlobeNewswire
Mar-09-18 12:01PM  DBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Mar-07-18 01:31AM  DBV Technologies to Present at the Barclays Global Healthcare Conference GlobeNewswire
Mar-05-18 02:24PM  This Biotech Could Have A Blockbuster Should It Partner With Big Pharma? Investor's Business Daily
Mar-01-18 07:01AM  Heres Whats Important About The Latest DBV Data Market Exclusive
Feb-26-18 05:07PM  DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients GlobeNewswire
Feb-20-18 01:32AM  DBV Technologies Reports December 31, 2017 Cash Position GlobeNewswire
Feb-14-18 01:18PM  Why DBV Technologies Jumped Higher Today Motley Fool +25.74%
08:10AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
01:32AM  DBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut GlobeNewswire
Feb-13-18 08:17AM  DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Feb-12-18 09:02AM  DBV Technologies présente de nouveaux résultats lors du Congrès Annuel 2018 de l'AAAAI/WAO concernant sa plateforme Viaskin GlobeNewswire
Feb-01-18 01:31AM  DBV Technologies to Attend Upcoming Investor Conferences GlobeNewswire
Jan-16-18 01:32AM  Half-Year Report on DBV Technologies Liquidity Contract with Natixis GlobeNewswire -5.71%
Jan-12-18 10:10AM  DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Jan-08-18 01:19PM  How To Trade The JPMorgan Healthcare Conference Benzinga
Jan-03-18 01:31AM  DBV Technologies to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-22-17 06:31AM  DBV Technologies :Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Dec-05-17 11:11AM  DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Dec-04-17 01:32AM  DBV Technologies CEO, Chairman, and Co-Founder, Dr. Pierre-Henri Benhamou Recognized for His Lasting Impact on the Food Allergy Community and Research Advancement by FARE (Food Allergy Research & E... GlobeNewswire
Dec-01-17 09:35AM  Versartis Pops, DBV Wild Ride Continues -- Biotech Movers TheStreet.com
Nov-28-17 09:41AM  DBV Technologies to Attend Citi's 2017 Global Healthcare Conference GlobeNewswire
03:12AM  DBV Technologies to Attend Citi's 2017 Global Healthcare Conference Marketwired
Nov-27-17 09:40AM  This French Biotech Is Pushing Its Peanut Allergy Patch Despite a Failed Study Bloomberg
Nov-20-17 08:33PM  DBVT Rises On Data for Peanut Allergy Drug; Bitcoin Rockets Past $8,000 -- ICYMI TheStreet.com +10.97%
09:24AM  DBV Rises On Phase 3 Results for Peanut Allergy Treatment -- Biotech Movers TheStreet.com
01:32AM  DBV Technologies Announces Positive Topline Safety Results from REALISE Phase III Trial of Viaskin Peanut for the Treatment of Peanut-Allergic Patients GlobeNewswire
Nov-14-17 11:32AM  DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut in the Journal of the American Medical Association GlobeNewswire
Nov-13-17 09:18AM  DBV Technologies :Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Oct-24-17 09:22AM  Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers TheStreet.com
Oct-23-17 04:04PM  Eldorado Gold, DBV Technologies Crash into Mondays 52-Week Low Club 24/7 Wall St. -41.09%
01:46PM  DBV Technologies Pain is Aimmune Therapeutics Incs (AIMT) Gain SmarterAnalyst
01:27PM  Why DBV Technologies SA Plummeted and Aimmune Therapeutics Inc Skyrocketed Today Motley Fool
12:48PM  What Spooked DBV Technologies SA ADR (DBVT) Investors Today SmarterAnalyst
09:15AM  DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers TheStreet.com
04:47AM  French Drugmaker Crashes After Peanut Allergy Treatment Fails a Major Trial Bloomberg
Oct-20-17 06:17PM  DBV Technologies Plunges By Half On Allergy Drug Trial's Failure Investor's Business Daily
04:49PM  DBV Technologies peanut allergy drug fails key study Reuters
Oct-18-17 10:54AM  [$$] Aimmune, DBV: Fighting Over More Than Peanuts Barrons.com
Oct-12-17 01:32AM  DBV Technologies Announces Completion of Blinded Period in REALISE Study of Viaskin Peanut GlobeNewswire
Sep-01-17 01:32AM  DBV Technologies to Attend Upcoming Investor Conferences GlobeNewswire
Aug-29-17 01:32AM  DBV Technologies Announces Completion of Enrollment in Phase III Extension Study of Viaskin Peanut GlobeNewswire
Aug-25-17 05:04AM  DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Aug-22-17 12:38PM  DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Aug-02-17 01:32AM  DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Three Years of Age GlobeNewswire
Jul-28-17 01:32AM  DBV Technologies Reports First Half 2017 Financial Results GlobeNewswire
Jul-10-17 08:38AM  DBV Technologies (DBVT) Worth a Look: Stock Up 5.7% Zacks
Jul-07-17 06:44AM  DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire +5.75%
Jul-05-17 04:32PM  Half-Year Report on the DBV Technologies Liquidity Contract with Natixis GlobeNewswire
Jun-17-17 02:32AM  DBV Technologies Highlights Poster Presentations on EPIT® at the 2017 EAACI Congress GlobeNewswire
Jun-15-17 04:32PM  DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting GlobeNewswire
04:32PM  DBV Technologies Announces Appointment of Julie O'Neill to Board of Directors GlobeNewswire
Jun-12-17 05:22AM  DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Jun-01-17 01:32AM  DBV Technologies to Attend Upcoming Investor Conferences GlobeNewswire
May-24-17 04:31PM  DBV Technologies : Ordinary and Extraordinary General Meeting of June 15, 2017 Procedures for Obtaining Preparatory Documents for the General Meeting GlobeNewswire
May-12-17 04:18AM  DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
May-08-17 01:32AM  DBV Technologies Highlights Research Presentation of EPIT® for the Treatment of Crohn's Disease at Digestive Disease Week 2017 GlobeNewswire
May-02-17 01:32AM  DBV Technologies to Attend Upcoming Investor Conferences GlobeNewswire
Apr-28-17 01:32AM  DBV Technologies Reports March 31, 2017 Cash Position GlobeNewswire
Apr-05-17 10:29AM  DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
10:29AM  DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company
01:32AM  DBV Technologies to Attend the 10th Kempen Life Sciences Conference GlobeNewswire
01:32AM  DBV Technologies to Attend the 10th Kempen Life Sciences Conference
Mar-30-17 04:32PM  DBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination GlobeNewswire
Mar-28-17 01:04PM  DBV TECHNOLOGIES S.A. Financials
Mar-22-17 05:32PM  DBV Technologies : Announces Filing of its 2016 "Document de Référence" and Annual Report on Form 20-F GlobeNewswire
Mar-16-17 08:56AM  DBV Technologies upgraded by Societe Generale
Mar-15-17 02:31AM  DBV Technologies Reports Full Year 2016 Financial Results GlobeNewswire
Mar-10-17 01:32AM  DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children GlobeNewswire
Mar-09-17 07:00AM  7 Stocks Trending Up With Monster Volume TheStreet.com
07:00AM  7 Stocks Trending Up With Monster Volume
Mar-07-17 09:01AM  DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Mar-05-17 03:47PM  DBV Technologies :Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children GlobeNewswire
02:15PM  A patch could fix your peanut-allergy problem Business Insider
02:15PM  A patch could fix your peanut-allergy problem
Mar-01-17 01:32AM  DBV Technologies to Attend Upcoming Investor Conferences GlobeNewswire
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestle Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.